{"id":"NCT00280566","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)","officialTitle":"A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-01-23","resultsPosted":"2009-12-14","lastUpdate":"2021-03-25"},"enrollment":584,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Mania","Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Ziprasidone Oral Capsule","otherNames":["Geodon, Zeldox"]}],"arms":[{"label":"Ziprasidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen.","primaryOutcome":{"measure":"Time to Intervention for a Mood Episode During Double Blind Period","timeFrame":"Period 2: 24 weeks or time of early termination","effectByArm":[{"arm":"Ziprasidone","deltaMin":172.159,"sd":5.646},{"arm":"Placebo","deltaMin":143.133,"sd":7.532}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0104"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":107,"countries":["United States","Chile","France","Germany","Guatemala","Hong Kong","India","Italy","Mexico","Russia","Spain","Taiwan","Venezuela"]},"refs":{"pmids":["20122373"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281137&StudyName=Safety%20and%20Maintenance%20of%20Effect%20of%20Ziprasidone%20Plus%20a%20Mood%20Stabilizer%20in%20Bipolar%20I%20Disorder%20%28manic%20or%20mixed%29"]},"adverseEventsSummary":{"seriousAny":{"events":15},"commonTop":["Sedation","Somnolence","Tremor","Insomnia","Dizziness"]}}